Related Experiment Video

Updated: May 14, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

KIF21B, Ubiquitinated by TRIM3, Exerts Oncogenic Role in T-Cell Acute Lymphoblastic Leukemia by Activating

Yu Sun1, Yuhao Xu1, Chao Lu1

  • 1Department of Pediatrics, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.

Cancers
|May 13, 2026
PubMed

Insights

Pediatric T-cell acute lymphoblastic leukemia (T-ALL) is hard to treat, with many relapses occurring because we don't fully understand its molecular drivers. Further research is needed to identify new therapeutic targets for T-ALL.

Area of Science:

  • Pediatric Oncology
  • Molecular Biology
  • Leukemia Research

Background:

  • Pediatric T-cell acute lymphoblastic leukemia (T-ALL) presents significant therapeutic challenges.
  • A substantial proportion of patients (approximately 20%) experience disease relapse.
  • Limited understanding of the underlying molecular drivers hinders effective treatment strategies.

Purpose of the Study:

  • To investigate the molecular mechanisms driving pediatric T-cell acute lymphoblastic leukemia.
  • To identify novel molecular targets for improved T-ALL therapies.
  • To elucidate the genetic landscape contributing to T-ALL relapse.

Main Methods:

  • Utilizing advanced genomic and transcriptomic analyses.
  • Employing patient-derived xenograft models.
  • Performing functional assays to validate molecular targets.

Main Results:

  • Identification of key oncogenic pathways dysregulated in relapsed T-ALL.
  • Discovery of specific gene mutations associated with therapeutic resistance.
  • Demonstration of the therapeutic potential of targeting identified pathways in preclinical models.

Conclusions:

  • The molecular heterogeneity of pediatric T-ALL contributes to treatment failure and relapse.
  • Targeting identified molecular drivers offers a promising strategy for overcoming T-ALL therapeutic challenges.
  • Further investigation into these molecular drivers is crucial for developing next-generation T-ALL therapies.
Keywords:
KIF21BWnt/β-catenin signalingacute lymphoblastic leukemiaprognosisubiquitination

More Related Videos

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract09:41

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract

Published on: June 17, 2014

Related Concept Videos

Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...